nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—skull—brain cancer	0.0506	0.252	CbGeAlD
Lenalidomide—PTGS2—Etoposide—brain cancer	0.0311	0.752	CbGbCtD
Lenalidomide—TNFSF11—Differentiation Pathway—ALK—brain cancer	0.0238	0.118	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—CLDN6—brain cancer	0.0189	0.0936	CbGpPWpGaD
Lenalidomide—CDH5—endothelium—brain cancer	0.0171	0.0851	CbGeAlD
Lenalidomide—CDH5—blood vessel—brain cancer	0.0157	0.0784	CbGeAlD
Lenalidomide—TNFSF11—Osteoblast Signaling—PDGFRA—brain cancer	0.0157	0.0777	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CLDN6—brain cancer	0.0143	0.0708	CbGpPWpGaD
Lenalidomide—TNFSF11—Osteoclast Signaling—SPP1—brain cancer	0.0137	0.0678	CbGpPWpGaD
Lenalidomide—ABCB1—Etoposide—brain cancer	0.0103	0.248	CbGbCtD
Lenalidomide—CDH5—Cell-Cell communication—CLDN6—brain cancer	0.0102	0.0504	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—SHH—brain cancer	0.00988	0.049	CbGpPWpGaD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—VAV1—brain cancer	0.00832	0.0413	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—VAV1—brain cancer	0.00726	0.036	CbGpPWpGaD
Lenalidomide—TNFSF11—endocrine gland—brain cancer	0.0064	0.0319	CbGeAlD
Lenalidomide—TNFSF11—head—brain cancer	0.00632	0.0315	CbGeAlD
Lenalidomide—Thalidomide—CYP2C9—brain cancer	0.00631	1	CrCbGaD
Lenalidomide—CDH5—pituitary gland—brain cancer	0.00622	0.031	CbGeAlD
Lenalidomide—CDH5—medulla oblongata—brain cancer	0.006	0.0299	CbGeAlD
Lenalidomide—CDH5—midbrain—brain cancer	0.00549	0.0273	CbGeAlD
Lenalidomide—CDH5—spinal cord—brain cancer	0.00535	0.0267	CbGeAlD
Lenalidomide—CRBN—telencephalon—brain cancer	0.00485	0.0242	CbGeAlD
Lenalidomide—CDH5—endocrine gland—brain cancer	0.00482	0.024	CbGeAlD
Lenalidomide—CDH5—head—brain cancer	0.00476	0.0237	CbGeAlD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—S100A6—brain cancer	0.00443	0.022	CbGpPWpGaD
Lenalidomide—CDH5—central nervous system—brain cancer	0.00434	0.0216	CbGeAlD
Lenalidomide—CDH5—cerebellum—brain cancer	0.00424	0.0211	CbGeAlD
Lenalidomide—CRBN—gonad—brain cancer	0.00405	0.0202	CbGeAlD
Lenalidomide—CRBN—pituitary gland—brain cancer	0.00395	0.0197	CbGeAlD
Lenalidomide—CRBN—medulla oblongata—brain cancer	0.00381	0.019	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—CTNNB1—brain cancer	0.00359	0.0178	CbGpPWpGaD
Lenalidomide—CRBN—midbrain—brain cancer	0.00348	0.0174	CbGeAlD
Lenalidomide—CDH5—brain—brain cancer	0.00345	0.0172	CbGeAlD
Lenalidomide—CRBN—spinal cord—brain cancer	0.0034	0.0169	CbGeAlD
Lenalidomide—CDH5—Adherens junctions interactions—CTNNB1—brain cancer	0.0034	0.0169	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—RELA—brain cancer	0.00317	0.0157	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—S100A10—brain cancer	0.00307	0.0152	CbGpPWpGaD
Lenalidomide—CRBN—endocrine gland—brain cancer	0.00306	0.0152	CbGeAlD
Lenalidomide—CRBN—head—brain cancer	0.00302	0.0151	CbGeAlD
Lenalidomide—PTGS2—endothelium—brain cancer	0.00295	0.0147	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VAV1—brain cancer	0.00285	0.0141	CbGpPWpGaD
Lenalidomide—CRBN—central nervous system—brain cancer	0.00276	0.0137	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—STAT3—brain cancer	0.00273	0.0135	CbGpPWpGaD
Lenalidomide—PTGS2—blood vessel—brain cancer	0.00272	0.0136	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—brain cancer	0.00271	0.0134	CbGpPWpGaD
Lenalidomide—CRBN—cerebellum—brain cancer	0.0027	0.0134	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—VAV1—brain cancer	0.00269	0.0133	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—brain cancer	0.00254	0.0126	CbGpPWpGaD
Lenalidomide—CRBN—brain—brain cancer	0.00219	0.0109	CbGeAlD
Lenalidomide—CDH5—Cell-cell junction organization—CTNNB1—brain cancer	0.00195	0.00968	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—brain cancer	0.00177	0.00876	CbGpPWpGaD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.00171	0.0085	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.00169	0.00839	CbGpPWpGaD
Lenalidomide—ABCB1—blood vessel—brain cancer	0.00168	0.00839	CbGeAlD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00163	0.0081	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—brain cancer	0.00155	0.00771	CbGpPWpGaD
Lenalidomide—CDH5—Cell junction organization—CTNNB1—brain cancer	0.00148	0.00733	CbGpPWpGaD
Lenalidomide—PTGS2—telencephalon—brain cancer	0.00132	0.00658	CbGeAlD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—CTNNB1—brain cancer	0.00123	0.00609	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—OR4C12—brain cancer	0.00116	0.00576	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—OR14C36—brain cancer	0.00116	0.00576	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—CTNNB1—brain cancer	0.00116	0.00575	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—brain cancer	0.00108	0.00536	CbGpPWpGaD
Lenalidomide—PTGS2—pituitary gland—brain cancer	0.00108	0.00536	CbGeAlD
Lenalidomide—CDH5—Cell-Cell communication—CTNNB1—brain cancer	0.00105	0.00521	CbGpPWpGaD
Lenalidomide—PTGS2—medulla oblongata—brain cancer	0.00104	0.00517	CbGeAlD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—brain cancer	0.00102	0.00506	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—DTX2—brain cancer	0.000988	0.0049	CbGpPWpGaD
Lenalidomide—PTGS2—midbrain—brain cancer	0.000949	0.00473	CbGeAlD
Lenalidomide—PTGS2—spinal cord—brain cancer	0.000926	0.00461	CbGeAlD
Lenalidomide—PTGS2—endocrine gland—brain cancer	0.000833	0.00415	CbGeAlD
Lenalidomide—PTGS2—head—brain cancer	0.000823	0.0041	CbGeAlD
Lenalidomide—ABCB1—telencephalon—brain cancer	0.000817	0.00407	CbGeAlD
Lenalidomide—PTGS2—central nervous system—brain cancer	0.000751	0.00374	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—PTCH2—brain cancer	0.000748	0.00371	CbGpPWpGaD
Lenalidomide—PTGS2—cerebellum—brain cancer	0.000734	0.00366	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—HES5—brain cancer	0.000725	0.0036	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STRADA—brain cancer	0.000704	0.00349	CbGpPWpGaD
Lenalidomide—ABCB1—gonad—brain cancer	0.000682	0.0034	CbGeAlD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000667	0.00331	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—brain cancer	0.000667	0.00331	CbGpPWpGaD
Lenalidomide—ABCB1—pituitary gland—brain cancer	0.000665	0.00331	CbGeAlD
Lenalidomide—ABCB1—medulla oblongata—brain cancer	0.000642	0.0032	CbGeAlD
Lenalidomide—PTGS2—Spinal Cord Injury—GFAP—brain cancer	0.000622	0.00309	CbGpPWpGaD
Lenalidomide—PTGS2—brain—brain cancer	0.000596	0.00297	CbGeAlD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000595	0.00295	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ABR—brain cancer	0.000587	0.00291	CbGpPWpGaD
Lenalidomide—ABCB1—midbrain—brain cancer	0.000587	0.00292	CbGeAlD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—brain cancer	0.000581	0.00288	CbGpPWpGaD
Lenalidomide—ABCB1—spinal cord—brain cancer	0.000573	0.00285	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—GLI2—brain cancer	0.000567	0.00281	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDK6—brain cancer	0.000545	0.0027	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GLI1—brain cancer	0.000533	0.00265	CbGpPWpGaD
Lenalidomide—ABCB1—endocrine gland—brain cancer	0.000516	0.00257	CbGeAlD
Lenalidomide—ABCB1—head—brain cancer	0.000509	0.00254	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—SUFU—brain cancer	0.000506	0.00251	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—brain cancer	0.000488	0.00242	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GFAP—brain cancer	0.000488	0.00242	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—brain cancer	0.000476	0.00236	CbGpPWpGaD
Lenalidomide—ABCB1—central nervous system—brain cancer	0.000465	0.00231	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—HEY1—brain cancer	0.000462	0.00229	CbGpPWpGaD
Lenalidomide—ABCB1—cerebellum—brain cancer	0.000454	0.00226	CbGeAlD
Lenalidomide—CDH5—Signaling Pathways—DLL1—brain cancer	0.000453	0.00225	CbGpPWpGaD
Lenalidomide—Hallucination—Carmustine—brain cancer	0.000422	0.000767	CcSEcCtD
Lenalidomide—Hypoaesthesia—Carmustine—brain cancer	0.000422	0.000767	CcSEcCtD
Lenalidomide—Decreased appetite—Procarbazine—brain cancer	0.000419	0.000761	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Etoposide—brain cancer	0.000418	0.00076	CcSEcCtD
Lenalidomide—Oedema peripheral—Carmustine—brain cancer	0.000418	0.000759	CcSEcCtD
Lenalidomide—Connective tissue disorder—Carmustine—brain cancer	0.000417	0.000758	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	0.000417	0.00207	CbGpPWpGaD
Lenalidomide—Fatigue—Procarbazine—brain cancer	0.000415	0.000755	CcSEcCtD
Lenalidomide—Haemoglobin—Temozolomide—brain cancer	0.000412	0.000749	CcSEcCtD
Lenalidomide—Malaise—Hydroxyurea—brain cancer	0.000412	0.000749	CcSEcCtD
Lenalidomide—Constipation—Procarbazine—brain cancer	0.000412	0.000749	CcSEcCtD
Lenalidomide—Pain—Procarbazine—brain cancer	0.000412	0.000749	CcSEcCtD
Lenalidomide—Hepatitis—Temozolomide—brain cancer	0.00041	0.000745	CcSEcCtD
Lenalidomide—Haemorrhage—Temozolomide—brain cancer	0.00041	0.000745	CcSEcCtD
Lenalidomide—Dysphagia—Etoposide—brain cancer	0.00041	0.000745	CcSEcCtD
Lenalidomide—Leukopenia—Hydroxyurea—brain cancer	0.000409	0.000743	CcSEcCtD
Lenalidomide—Visual impairment—Carmustine—brain cancer	0.000409	0.000743	CcSEcCtD
Lenalidomide—Hallucination—Temozolomide—brain cancer	0.000408	0.000741	CcSEcCtD
Lenalidomide—Hypoaesthesia—Temozolomide—brain cancer	0.000408	0.000741	CcSEcCtD
Lenalidomide—Pharyngitis—Temozolomide—brain cancer	0.000407	0.000739	CcSEcCtD
Lenalidomide—Urinary tract disorder—Temozolomide—brain cancer	0.000405	0.000736	CcSEcCtD
Lenalidomide—Oedema peripheral—Temozolomide—brain cancer	0.000404	0.000734	CcSEcCtD
Lenalidomide—Connective tissue disorder—Temozolomide—brain cancer	0.000403	0.000732	CcSEcCtD
Lenalidomide—Urethral disorder—Temozolomide—brain cancer	0.000402	0.00073	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HES1—brain cancer	0.000401	0.00199	CbGpPWpGaD
Lenalidomide—Sweating increased—Etoposide—brain cancer	0.000399	0.000725	CcSEcCtD
Lenalidomide—Feeling abnormal—Procarbazine—brain cancer	0.000397	0.000721	CcSEcCtD
Lenalidomide—Eye disorder—Carmustine—brain cancer	0.000396	0.00072	CcSEcCtD
Lenalidomide—Visual impairment—Temozolomide—brain cancer	0.000395	0.000718	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Procarbazine—brain cancer	0.000394	0.000716	CcSEcCtD
Lenalidomide—Flushing—Carmustine—brain cancer	0.000393	0.000715	CcSEcCtD
Lenalidomide—Pancytopenia—Etoposide—brain cancer	0.000389	0.000707	CcSEcCtD
Lenalidomide—Erythema multiforme—Temozolomide—brain cancer	0.000387	0.000704	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000386	0.000702	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—brain cancer	0.000386	0.00191	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SHH—brain cancer	0.000386	0.00191	CbGpPWpGaD
Lenalidomide—Discomfort—Hydroxyurea—brain cancer	0.000384	0.000698	CcSEcCtD
Lenalidomide—Neutropenia—Etoposide—brain cancer	0.000383	0.000696	CcSEcCtD
Lenalidomide—Eye disorder—Temozolomide—brain cancer	0.000383	0.000696	CcSEcCtD
Lenalidomide—Urticaria—Procarbazine—brain cancer	0.000382	0.000695	CcSEcCtD
Lenalidomide—Tinnitus—Temozolomide—brain cancer	0.000382	0.000695	CcSEcCtD
Lenalidomide—Abdominal pain—Procarbazine—brain cancer	0.000381	0.000692	CcSEcCtD
Lenalidomide—Body temperature increased—Procarbazine—brain cancer	0.000381	0.000692	CcSEcCtD
Lenalidomide—Cardiac disorder—Temozolomide—brain cancer	0.00038	0.000691	CcSEcCtD
Lenalidomide—Flushing—Temozolomide—brain cancer	0.00038	0.000691	CcSEcCtD
Lenalidomide—Arrhythmia—Carmustine—brain cancer	0.000379	0.000689	CcSEcCtD
Lenalidomide—Alopecia—Carmustine—brain cancer	0.000375	0.000681	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RELA—brain cancer	0.000374	0.00186	CbGpPWpGaD
Lenalidomide—Oedema—Hydroxyurea—brain cancer	0.000373	0.000677	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TRPC6—brain cancer	0.000372	0.00184	CbGpPWpGaD
Lenalidomide—Angiopathy—Temozolomide—brain cancer	0.000372	0.000676	CcSEcCtD
Lenalidomide—Mental disorder—Carmustine—brain cancer	0.000371	0.000675	CcSEcCtD
Lenalidomide—Infection—Hydroxyurea—brain cancer	0.00037	0.000673	CcSEcCtD
Lenalidomide—Immune system disorder—Temozolomide—brain cancer	0.00037	0.000673	CcSEcCtD
Lenalidomide—Mediastinal disorder—Temozolomide—brain cancer	0.000369	0.000671	CcSEcCtD
Lenalidomide—Erythema—Carmustine—brain cancer	0.000369	0.000671	CcSEcCtD
Lenalidomide—Malnutrition—Carmustine—brain cancer	0.000369	0.000671	CcSEcCtD
Lenalidomide—ABCB1—brain—brain cancer	0.000369	0.00184	CbGeAlD
Lenalidomide—Chills—Temozolomide—brain cancer	0.000368	0.000668	CcSEcCtD
Lenalidomide—Pneumonia—Etoposide—brain cancer	0.000367	0.000668	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTCH1—brain cancer	0.000365	0.00181	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SMO—brain cancer	0.000365	0.00181	CbGpPWpGaD
Lenalidomide—Nervous system disorder—Hydroxyurea—brain cancer	0.000365	0.000664	CcSEcCtD
Lenalidomide—Infestation—Etoposide—brain cancer	0.000365	0.000664	CcSEcCtD
Lenalidomide—Infestation NOS—Etoposide—brain cancer	0.000365	0.000664	CcSEcCtD
Lenalidomide—Thrombocytopenia—Hydroxyurea—brain cancer	0.000365	0.000663	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000362	0.000658	CcSEcCtD
Lenalidomide—Alopecia—Temozolomide—brain cancer	0.000362	0.000658	CcSEcCtD
Lenalidomide—Skin disorder—Hydroxyurea—brain cancer	0.000362	0.000658	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Etoposide—brain cancer	0.00036	0.000655	CcSEcCtD
Lenalidomide—Renal failure—Etoposide—brain cancer	0.000359	0.000653	CcSEcCtD
Lenalidomide—Mental disorder—Temozolomide—brain cancer	0.000359	0.000653	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Etoposide—brain cancer	0.000358	0.000651	CcSEcCtD
Lenalidomide—Myocardial infarction—Etoposide—brain cancer	0.000358	0.000651	CcSEcCtD
Lenalidomide—Back pain—Carmustine—brain cancer	0.000357	0.000649	CcSEcCtD
Lenalidomide—Erythema—Temozolomide—brain cancer	0.000357	0.000648	CcSEcCtD
Lenalidomide—Malnutrition—Temozolomide—brain cancer	0.000357	0.000648	CcSEcCtD
Lenalidomide—Stomatitis—Etoposide—brain cancer	0.000356	0.000647	CcSEcCtD
Lenalidomide—Anorexia—Hydroxyurea—brain cancer	0.000355	0.000646	CcSEcCtD
Lenalidomide—Hypersensitivity—Procarbazine—brain cancer	0.000355	0.000645	CcSEcCtD
Lenalidomide—Dysgeusia—Temozolomide—brain cancer	0.000349	0.000635	CcSEcCtD
Lenalidomide—Vision blurred—Carmustine—brain cancer	0.000348	0.000632	CcSEcCtD
Lenalidomide—Tremor—Carmustine—brain cancer	0.000346	0.000629	CcSEcCtD
Lenalidomide—Asthenia—Procarbazine—brain cancer	0.000345	0.000628	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Etoposide—brain cancer	0.000345	0.000628	CcSEcCtD
Lenalidomide—Back pain—Temozolomide—brain cancer	0.000345	0.000627	CcSEcCtD
Lenalidomide—Anaemia—Carmustine—brain cancer	0.000341	0.00062	CcSEcCtD
Lenalidomide—Agranulocytosis—Etoposide—brain cancer	0.000341	0.00062	CcSEcCtD
Lenalidomide—Pruritus—Procarbazine—brain cancer	0.000341	0.000619	CcSEcCtD
Lenalidomide—Agitation—Carmustine—brain cancer	0.000339	0.000617	CcSEcCtD
Lenalidomide—Vision blurred—Temozolomide—brain cancer	0.000336	0.000611	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000334	0.00166	CbGpPWpGaD
Lenalidomide—Tremor—Temozolomide—brain cancer	0.000334	0.000608	CcSEcCtD
Lenalidomide—Dyspnoea—Hydroxyurea—brain cancer	0.000332	0.000604	CcSEcCtD
Lenalidomide—Somnolence—Hydroxyurea—brain cancer	0.000331	0.000602	CcSEcCtD
Lenalidomide—Ill-defined disorder—Temozolomide—brain cancer	0.000331	0.000602	CcSEcCtD
Lenalidomide—Leukopenia—Carmustine—brain cancer	0.00033	0.000601	CcSEcCtD
Lenalidomide—Anaemia—Temozolomide—brain cancer	0.00033	0.000599	CcSEcCtD
Lenalidomide—Diarrhoea—Procarbazine—brain cancer	0.000329	0.000599	CcSEcCtD
Lenalidomide—Dyspepsia—Hydroxyurea—brain cancer	0.000328	0.000596	CcSEcCtD
Lenalidomide—Agitation—Temozolomide—brain cancer	0.000328	0.000596	CcSEcCtD
Lenalidomide—Hypoaesthesia—Etoposide—brain cancer	0.000326	0.000593	CcSEcCtD
Lenalidomide—Angioedema—Temozolomide—brain cancer	0.000326	0.000593	CcSEcCtD
Lenalidomide—Decreased appetite—Hydroxyurea—brain cancer	0.000324	0.000589	CcSEcCtD
Lenalidomide—Urinary tract disorder—Etoposide—brain cancer	0.000324	0.000589	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000322	0.000585	CcSEcCtD
Lenalidomide—Malaise—Temozolomide—brain cancer	0.000322	0.000585	CcSEcCtD
Lenalidomide—Urethral disorder—Etoposide—brain cancer	0.000321	0.000584	CcSEcCtD
Lenalidomide—Fatigue—Hydroxyurea—brain cancer	0.000321	0.000584	CcSEcCtD
Lenalidomide—Vertigo—Temozolomide—brain cancer	0.00032	0.000583	CcSEcCtD
Lenalidomide—Leukopenia—Temozolomide—brain cancer	0.000319	0.00058	CcSEcCtD
Lenalidomide—Hypertension—Carmustine—brain cancer	0.000319	0.000579	CcSEcCtD
Lenalidomide—Constipation—Hydroxyurea—brain cancer	0.000319	0.000579	CcSEcCtD
Lenalidomide—Pain—Hydroxyurea—brain cancer	0.000319	0.000579	CcSEcCtD
Lenalidomide—Dizziness—Procarbazine—brain cancer	0.000318	0.000579	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000317	0.00157	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—brain cancer	0.000315	0.00157	CbGpPWpGaD
Lenalidomide—Palpitations—Temozolomide—brain cancer	0.000315	0.000573	CcSEcCtD
Lenalidomide—Myalgia—Carmustine—brain cancer	0.000314	0.000571	CcSEcCtD
Lenalidomide—Chest pain—Carmustine—brain cancer	0.000314	0.000571	CcSEcCtD
Lenalidomide—Anxiety—Carmustine—brain cancer	0.000313	0.000569	CcSEcCtD
Lenalidomide—Cough—Temozolomide—brain cancer	0.000311	0.000566	CcSEcCtD
Lenalidomide—Erythema multiforme—Etoposide—brain cancer	0.00031	0.000564	CcSEcCtD
Lenalidomide—Hypertension—Temozolomide—brain cancer	0.000308	0.00056	CcSEcCtD
Lenalidomide—Feeling abnormal—Hydroxyurea—brain cancer	0.000307	0.000558	CcSEcCtD
Lenalidomide—Eye disorder—Etoposide—brain cancer	0.000306	0.000557	CcSEcCtD
Lenalidomide—Vomiting—Procarbazine—brain cancer	0.000306	0.000557	CcSEcCtD
Lenalidomide—Flushing—Etoposide—brain cancer	0.000304	0.000553	CcSEcCtD
Lenalidomide—Cardiac disorder—Etoposide—brain cancer	0.000304	0.000553	CcSEcCtD
Lenalidomide—Confusional state—Carmustine—brain cancer	0.000304	0.000552	CcSEcCtD
Lenalidomide—Arthralgia—Temozolomide—brain cancer	0.000304	0.000552	CcSEcCtD
Lenalidomide—Myalgia—Temozolomide—brain cancer	0.000304	0.000552	CcSEcCtD
Lenalidomide—Rash—Procarbazine—brain cancer	0.000304	0.000552	CcSEcCtD
Lenalidomide—Dermatitis—Procarbazine—brain cancer	0.000303	0.000551	CcSEcCtD
Lenalidomide—Anxiety—Temozolomide—brain cancer	0.000303	0.00055	CcSEcCtD
Lenalidomide—Headache—Procarbazine—brain cancer	0.000302	0.000548	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.000302	0.000548	CcSEcCtD
Lenalidomide—Oedema—Carmustine—brain cancer	0.000301	0.000548	CcSEcCtD
Lenalidomide—Discomfort—Temozolomide—brain cancer	0.0003	0.000545	CcSEcCtD
Lenalidomide—Infection—Carmustine—brain cancer	0.000299	0.000544	CcSEcCtD
Lenalidomide—Angiopathy—Etoposide—brain cancer	0.000297	0.000541	CcSEcCtD
Lenalidomide—Dry mouth—Temozolomide—brain cancer	0.000297	0.00054	CcSEcCtD
Lenalidomide—Immune system disorder—Etoposide—brain cancer	0.000296	0.000538	CcSEcCtD
Lenalidomide—Mediastinal disorder—Etoposide—brain cancer	0.000295	0.000537	CcSEcCtD
Lenalidomide—Thrombocytopenia—Carmustine—brain cancer	0.000295	0.000536	CcSEcCtD
Lenalidomide—Body temperature increased—Hydroxyurea—brain cancer	0.000295	0.000536	CcSEcCtD
Lenalidomide—Chills—Etoposide—brain cancer	0.000294	0.000535	CcSEcCtD
Lenalidomide—Tachycardia—Carmustine—brain cancer	0.000294	0.000535	CcSEcCtD
Lenalidomide—Confusional state—Temozolomide—brain cancer	0.000293	0.000534	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—NOTCH2—brain cancer	0.000292	0.00145	CbGpPWpGaD
Lenalidomide—Oedema—Temozolomide—brain cancer	0.000291	0.000529	CcSEcCtD
Lenalidomide—Alopecia—Etoposide—brain cancer	0.00029	0.000527	CcSEcCtD
Lenalidomide—Infection—Temozolomide—brain cancer	0.000289	0.000526	CcSEcCtD
Lenalidomide—Anorexia—Carmustine—brain cancer	0.000287	0.000522	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	0.000287	0.00142	CbGpPWpGaD
Lenalidomide—Nausea—Procarbazine—brain cancer	0.000286	0.00052	CcSEcCtD
Lenalidomide—Nervous system disorder—Temozolomide—brain cancer	0.000285	0.000519	CcSEcCtD
Lenalidomide—Thrombocytopenia—Temozolomide—brain cancer	0.000285	0.000518	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—PDGFRA—brain cancer	0.000284	0.00141	CbGpPWpGaD
Lenalidomide—Skin disorder—Temozolomide—brain cancer	0.000283	0.000514	CcSEcCtD
Lenalidomide—Hypotension—Carmustine—brain cancer	0.000281	0.000512	CcSEcCtD
Lenalidomide—Hyperhidrosis—Temozolomide—brain cancer	0.000281	0.000512	CcSEcCtD
Lenalidomide—Dysgeusia—Etoposide—brain cancer	0.000279	0.000508	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—VAV1—brain cancer	0.000279	0.00138	CbGpPWpGaD
Lenalidomide—Anorexia—Temozolomide—brain cancer	0.000277	0.000504	CcSEcCtD
Lenalidomide—Back pain—Etoposide—brain cancer	0.000276	0.000502	CcSEcCtD
Lenalidomide—Hypersensitivity—Hydroxyurea—brain cancer	0.000275	0.000499	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Carmustine—brain cancer	0.000274	0.000499	CcSEcCtD
Lenalidomide—Muscle spasms—Etoposide—brain cancer	0.000274	0.000499	CcSEcCtD
Lenalidomide—Insomnia—Carmustine—brain cancer	0.000272	0.000495	CcSEcCtD
Lenalidomide—Paraesthesia—Carmustine—brain cancer	0.00027	0.000492	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—brain cancer	0.000269	0.00134	CbGpPWpGaD
Lenalidomide—Dyspnoea—Carmustine—brain cancer	0.000269	0.000488	CcSEcCtD
Lenalidomide—Somnolence—Carmustine—brain cancer	0.000268	0.000487	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.000268	0.00133	CbGpPWpGaD
Lenalidomide—Asthenia—Hydroxyurea—brain cancer	0.000267	0.000486	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000265	0.000482	CcSEcCtD
Lenalidomide—Ill-defined disorder—Etoposide—brain cancer	0.000265	0.000481	CcSEcCtD
Lenalidomide—Anaemia—Etoposide—brain cancer	0.000264	0.00048	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—brain cancer	0.000264	0.00131	CbGpPWpGaD
Lenalidomide—Insomnia—Temozolomide—brain cancer	0.000263	0.000479	CcSEcCtD
Lenalidomide—Decreased appetite—Carmustine—brain cancer	0.000262	0.000476	CcSEcCtD
Lenalidomide—Paraesthesia—Temozolomide—brain cancer	0.000261	0.000475	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Carmustine—brain cancer	0.00026	0.000473	CcSEcCtD
Lenalidomide—Dyspnoea—Temozolomide—brain cancer	0.00026	0.000472	CcSEcCtD
Lenalidomide—Somnolence—Temozolomide—brain cancer	0.000259	0.000471	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	0.000258	0.00128	CbGpPWpGaD
Lenalidomide—Constipation—Carmustine—brain cancer	0.000258	0.000468	CcSEcCtD
Lenalidomide—Pain—Carmustine—brain cancer	0.000258	0.000468	CcSEcCtD
Lenalidomide—Malaise—Etoposide—brain cancer	0.000257	0.000468	CcSEcCtD
Lenalidomide—Vertigo—Etoposide—brain cancer	0.000256	0.000466	CcSEcCtD
Lenalidomide—Dyspepsia—Temozolomide—brain cancer	0.000256	0.000466	CcSEcCtD
Lenalidomide—Leukopenia—Etoposide—brain cancer	0.000255	0.000464	CcSEcCtD
Lenalidomide—Diarrhoea—Hydroxyurea—brain cancer	0.000255	0.000464	CcSEcCtD
Lenalidomide—Decreased appetite—Temozolomide—brain cancer	0.000253	0.00046	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Temozolomide—brain cancer	0.000251	0.000457	CcSEcCtD
Lenalidomide—Fatigue—Temozolomide—brain cancer	0.000251	0.000456	CcSEcCtD
Lenalidomide—Loss of consciousness—Etoposide—brain cancer	0.000251	0.000456	CcSEcCtD
Lenalidomide—Cough—Etoposide—brain cancer	0.000249	0.000453	CcSEcCtD
Lenalidomide—Pain—Temozolomide—brain cancer	0.000249	0.000453	CcSEcCtD
Lenalidomide—Constipation—Temozolomide—brain cancer	0.000249	0.000453	CcSEcCtD
Lenalidomide—Feeling abnormal—Carmustine—brain cancer	0.000248	0.000451	CcSEcCtD
Lenalidomide—Hypertension—Etoposide—brain cancer	0.000246	0.000448	CcSEcCtD
Lenalidomide—Dizziness—Hydroxyurea—brain cancer	0.000246	0.000448	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Carmustine—brain cancer	0.000246	0.000448	CcSEcCtD
Lenalidomide—Chest pain—Etoposide—brain cancer	0.000243	0.000442	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	0.000242	0.0012	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000241	0.000439	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—brain cancer	0.00024	0.00119	CbGpPWpGaD
Lenalidomide—Discomfort—Etoposide—brain cancer	0.00024	0.000436	CcSEcCtD
Lenalidomide—Feeling abnormal—Temozolomide—brain cancer	0.00024	0.000436	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CDK4—brain cancer	0.00024	0.00119	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HES1—brain cancer	0.00024	0.00119	CbGpPWpGaD
Lenalidomide—Abdominal pain—Carmustine—brain cancer	0.000238	0.000433	CcSEcCtD
Lenalidomide—Body temperature increased—Carmustine—brain cancer	0.000238	0.000433	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Temozolomide—brain cancer	0.000238	0.000433	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	0.000237	0.00118	CbGpPWpGaD
Lenalidomide—Vomiting—Hydroxyurea—brain cancer	0.000237	0.000431	CcSEcCtD
Lenalidomide—Rash—Hydroxyurea—brain cancer	0.000235	0.000427	CcSEcCtD
Lenalidomide—Confusional state—Etoposide—brain cancer	0.000235	0.000427	CcSEcCtD
Lenalidomide—Dermatitis—Hydroxyurea—brain cancer	0.000235	0.000427	CcSEcCtD
Lenalidomide—Headache—Hydroxyurea—brain cancer	0.000233	0.000424	CcSEcCtD
Lenalidomide—Infection—Etoposide—brain cancer	0.000231	0.000421	CcSEcCtD
Lenalidomide—Urticaria—Temozolomide—brain cancer	0.000231	0.00042	CcSEcCtD
Lenalidomide—Abdominal pain—Temozolomide—brain cancer	0.00023	0.000418	CcSEcCtD
Lenalidomide—Body temperature increased—Temozolomide—brain cancer	0.00023	0.000418	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PDGFRA—brain cancer	0.000228	0.00113	CbGpPWpGaD
Lenalidomide—Thrombocytopenia—Etoposide—brain cancer	0.000228	0.000415	CcSEcCtD
Lenalidomide—Tachycardia—Etoposide—brain cancer	0.000227	0.000413	CcSEcCtD
Lenalidomide—Skin disorder—Etoposide—brain cancer	0.000226	0.000411	CcSEcCtD
Lenalidomide—Hyperhidrosis—Etoposide—brain cancer	0.000225	0.000409	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	0.000225	0.00112	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—RELA—brain cancer	0.000223	0.00111	CbGpPWpGaD
Lenalidomide—Anorexia—Etoposide—brain cancer	0.000222	0.000404	CcSEcCtD
Lenalidomide—Hypersensitivity—Carmustine—brain cancer	0.000222	0.000403	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SPP1—brain cancer	0.000221	0.0011	CbGpPWpGaD
Lenalidomide—Nausea—Hydroxyurea—brain cancer	0.000221	0.000402	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.00022	0.00109	CbGpPWpGaD
Lenalidomide—Hypotension—Etoposide—brain cancer	0.000218	0.000396	CcSEcCtD
Lenalidomide—Asthenia—Carmustine—brain cancer	0.000216	0.000393	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.000216	0.00107	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Temozolomide—brain cancer	0.000214	0.00039	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.000213	0.00106	CbGpPWpGaD
Lenalidomide—Paraesthesia—Etoposide—brain cancer	0.000209	0.00038	CcSEcCtD
Lenalidomide—Asthenia—Temozolomide—brain cancer	0.000209	0.00038	CcSEcCtD
Lenalidomide—Dyspnoea—Etoposide—brain cancer	0.000208	0.000378	CcSEcCtD
Lenalidomide—Somnolence—Etoposide—brain cancer	0.000207	0.000376	CcSEcCtD
Lenalidomide—Diarrhoea—Carmustine—brain cancer	0.000206	0.000375	CcSEcCtD
Lenalidomide—Pruritus—Temozolomide—brain cancer	0.000206	0.000374	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—brain cancer	0.000203	0.00101	CbGpPWpGaD
Lenalidomide—Decreased appetite—Etoposide—brain cancer	0.000202	0.000368	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Etoposide—brain cancer	0.000201	0.000366	CcSEcCtD
Lenalidomide—Fatigue—Etoposide—brain cancer	0.000201	0.000365	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IRS2—brain cancer	0.0002	0.000993	CbGpPWpGaD
Lenalidomide—Dizziness—Carmustine—brain cancer	0.000199	0.000362	CcSEcCtD
Lenalidomide—Pain—Etoposide—brain cancer	0.000199	0.000362	CcSEcCtD
Lenalidomide—Constipation—Etoposide—brain cancer	0.000199	0.000362	CcSEcCtD
Lenalidomide—Diarrhoea—Temozolomide—brain cancer	0.000199	0.000362	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.000198	0.000982	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	0.000197	0.000975	CbGpPWpGaD
Lenalidomide—Dizziness—Temozolomide—brain cancer	0.000192	0.00035	CcSEcCtD
Lenalidomide—Feeling abnormal—Etoposide—brain cancer	0.000192	0.000349	CcSEcCtD
Lenalidomide—Vomiting—Carmustine—brain cancer	0.000192	0.000348	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Etoposide—brain cancer	0.00019	0.000346	CcSEcCtD
Lenalidomide—PTGS2—Disease—DTX2—brain cancer	0.00019	0.000944	CbGpPWpGaD
Lenalidomide—Rash—Carmustine—brain cancer	0.00019	0.000345	CcSEcCtD
Lenalidomide—Dermatitis—Carmustine—brain cancer	0.00019	0.000345	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	0.00019	0.000941	CbGpPWpGaD
Lenalidomide—Headache—Carmustine—brain cancer	0.000189	0.000343	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	0.000189	0.000935	CbGpPWpGaD
Lenalidomide—Vomiting—Temozolomide—brain cancer	0.000185	0.000337	CcSEcCtD
Lenalidomide—Urticaria—Etoposide—brain cancer	0.000185	0.000336	CcSEcCtD
Lenalidomide—Abdominal pain—Etoposide—brain cancer	0.000184	0.000335	CcSEcCtD
Lenalidomide—Body temperature increased—Etoposide—brain cancer	0.000184	0.000335	CcSEcCtD
Lenalidomide—Rash—Temozolomide—brain cancer	0.000184	0.000334	CcSEcCtD
Lenalidomide—Dermatitis—Temozolomide—brain cancer	0.000183	0.000333	CcSEcCtD
Lenalidomide—Headache—Temozolomide—brain cancer	0.000182	0.000332	CcSEcCtD
Lenalidomide—Nausea—Carmustine—brain cancer	0.000179	0.000325	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	0.000178	0.000882	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CG—brain cancer	0.000177	0.000877	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APC—brain cancer	0.000177	0.000877	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	0.000177	0.000877	CbGpPWpGaD
Lenalidomide—Nausea—Temozolomide—brain cancer	0.000173	0.000314	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—brain cancer	0.000172	0.000312	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—brain cancer	0.000167	0.000304	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—brain cancer	0.000165	0.0003	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	0.000163	0.000809	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—brain cancer	0.000163	0.000808	CbGpPWpGaD
Lenalidomide—Diarrhoea—Etoposide—brain cancer	0.000159	0.00029	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—brain cancer	0.000159	0.000787	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	0.000156	0.000773	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2—brain cancer	0.000155	0.000769	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—brain cancer	0.000155	0.000768	CbGpPWpGaD
Lenalidomide—Dizziness—Etoposide—brain cancer	0.000154	0.00028	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—brain cancer	0.000153	0.000761	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	0.000153	0.000758	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	0.000152	0.000755	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	0.000151	0.000749	CbGpPWpGaD
Lenalidomide—Vomiting—Etoposide—brain cancer	0.000148	0.000269	CcSEcCtD
Lenalidomide—Rash—Etoposide—brain cancer	0.000147	0.000267	CcSEcCtD
Lenalidomide—Dermatitis—Etoposide—brain cancer	0.000147	0.000267	CcSEcCtD
Lenalidomide—Headache—Etoposide—brain cancer	0.000146	0.000265	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	0.00014	0.000696	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HES5—brain cancer	0.00014	0.000693	CbGpPWpGaD
Lenalidomide—Nausea—Etoposide—brain cancer	0.000138	0.000252	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—RELA—brain cancer	0.000138	0.000686	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—brain cancer	0.000137	0.000681	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	0.000134	0.000663	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—brain cancer	0.000132	0.000654	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—brain cancer	0.000124	0.000617	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—brain cancer	0.000124	0.000616	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—brain cancer	0.000121	0.000602	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—brain cancer	0.000121	0.000602	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—brain cancer	0.00012	0.000596	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	0.000119	0.000591	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	0.000116	0.000573	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	0.000109	0.00054	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2C9—brain cancer	0.000108	0.000534	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—brain cancer	0.000106	0.000525	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	0.000105	0.000522	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—brain cancer	0.000105	0.00052	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	0.000104	0.000517	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—brain cancer	0.000102	0.000506	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—brain cancer	9.73e-05	0.000483	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—brain cancer	9.52e-05	0.000472	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IDH1—brain cancer	9.4e-05	0.000466	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	9.18e-05	0.000455	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BSG—brain cancer	9.15e-05	0.000454	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	9.08e-05	0.00045	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HEY1—brain cancer	8.91e-05	0.000442	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—DLL1—brain cancer	8.74e-05	0.000433	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	8.45e-05	0.000419	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	8.44e-05	0.000419	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	8.26e-05	0.00041	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—brain cancer	7.99e-05	0.000396	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—IDH1—brain cancer	7.87e-05	0.00039	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2C9—brain cancer	7.63e-05	0.000378	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	7.46e-05	0.00037	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO2—brain cancer	7.43e-05	0.000368	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SHH—brain cancer	7.43e-05	0.000368	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	7.39e-05	0.000367	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	6.93e-05	0.000344	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	6.5e-05	0.000323	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BSG—brain cancer	6.49e-05	0.000322	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	6.41e-05	0.000318	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO2—brain cancer	6.22e-05	0.000309	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	5.99e-05	0.000297	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	5.85e-05	0.00029	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—IDH1—brain cancer	5.58e-05	0.000277	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—VAV1—brain cancer	5.37e-05	0.000266	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	4.92e-05	0.000244	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HES1—brain cancer	4.62e-05	0.000229	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO2—brain cancer	4.41e-05	0.000219	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFRA—brain cancer	4.39e-05	0.000218	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IRS2—brain cancer	3.86e-05	0.000191	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—brain cancer	3.41e-05	0.000169	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—brain cancer	2.85e-05	0.000142	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—brain cancer	2.65e-05	0.000131	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—brain cancer	2.31e-05	0.000115	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—brain cancer	2.02e-05	0.0001	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—brain cancer	2.02e-05	0.0001	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—brain cancer	1.87e-05	9.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—brain cancer	1.83e-05	9.1e-05	CbGpPWpGaD
